Health Care [ 2/12 ] | Pharmaceuticals [ 27/74 ]
NASDAQ | Common Stock
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 26 | -0.39 Increased by +15.22% | -0.36 Decreased by -8.33% |
| May 6, 26 | -0.37 Increased by +11.90% | -0.34 Decreased by -8.82% |
| Mar 2, 26 | -0.30 Increased by +45.45% | -0.34 Increased by +11.76% |
| Nov 5, 25 | -0.37 Increased by +65.42% | -0.43 Increased by +13.95% |
| Aug 6, 25 | -0.46 Increased by +25.81% | -0.44 Decreased by -4.55% |
| May 7, 25 | -0.42 Decreased by -250.00% | -0.50 Increased by +16.00% |
| Mar 3, 25 | -0.55 Decreased by -885.71% | -0.56 Increased by +1.79% |
| Nov 6, 24 | -1.07 Decreased by -456.67% | -0.91 Decreased by -17.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 29, 26 | 0.00 Decreased by N/A% | -43.42 M Decreased by -4.78% | Decreased by N/A% Decreased by N/A% |
| Mar 30, 26 | 0.00 Decreased by N/A% | -41.28 M Decreased by -14.97% | Decreased by N/A% Decreased by N/A% |
| Dec 30, 25 | 0.00 Increased by +100.00% | -33.00 M Increased by +12.11% | Decreased by N/A% Decreased by N/A% |
| Sep 29, 25 | 0.00 Decreased by -100.00% | -34.39 M Increased by +52.70% | Decreased by N/A% Decreased by N/A% |
| Jun 29, 25 | 0.00 Increased by +100.00% | -41.44 M Increased by +42.99% | Decreased by N/A% Decreased by N/A% |
| Mar 30, 25 | 0.00 Decreased by -100.00% | -35.91 M Increased by +69.77% | Decreased by N/A% Decreased by N/A% |
| Dec 30, 24 | -665.00 K Decreased by -100.61% | -37.55 M Decreased by -893.62% | Increased by +5.65 K% Increased by +129.32 K% |
| Sep 29, 24 | 416.00 K Decreased by -99.59% | -72.70 M Decreased by -447.98% | Decreased by -17.48 K% Decreased by -86.00 K% |